Format

Send to

Choose Destination
Clin Infect Dis. 2018 May 17;66(11):1705-1711. doi: 10.1093/cid/cix1097.

Durability and Long-term Clinical Outcomes of Fecal Microbiota Transplant Treatment in Patients With Recurrent Clostridium difficile Infection.

Author information

1
Emory University School of Medicine, Atlanta, Georgia.
2
Division of Infectious Diseases, Emory University, Atlanta, Georgia.
3
Division of Digestive Diseases, Emory University, Atlanta, Georgia.
4
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia.

Abstract

Background:

Fecal microbiota transplant (FMT) appears safe and effective for treatment of recurrent Clostridium difficile infection (RCDI). However, durability, long-term clinical outcomes, and patient satisfaction after FMT are not well described.

Methods:

Eligible patients who received FMT for RCDI at Emory Hospital between 1 July 2012 and 31 December 2016 were contacted via telephone for a follow-up survey. Of 190 eligible patients, 137 (72%) completed the survey.

Results:

Median time from last FMT to follow-up was 22 months. Overall, 82% (113/137) of patients at follow-up had no recurrence of C. difficile infection (CDI) post-FMT (non-RCDI group) and 18% (24/137) of patients had CDI post-FMT (RCDI group). Antibiotic exposure for non-CDI infections after FMT was more common in the RCDI group compared to the non-RCDI group (75% vs 38%, P = .0009). Overall, 11% of patients reported improvement or resolution of diagnoses not related to CDI post-FMT, and 33% reported development of a new medical condition or symptom post-FMT. Ninety-five percent of patients (122/128) indicated that they would undergo FMT again, and 70% of these 122 reported that they would prefer FMT to antibiotics as initial treatment if they were to have a CDI recurrence.

Conclusions:

In this follow-up survey of outcomes after FMT at a median of 22 months follow-up, 82% of patients had durable cure of CDI. Patients with recurrence had more post-FMT antibiotic exposure, underscoring the need for thoughtful antibiotic use and a potential role for prophylactic microbiome enrichment to reduce recurrence.

PMID:
29272401
PMCID:
PMC5961001
[Available on 2019-05-17]
DOI:
10.1093/cid/cix1097

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center